Hemo Organic Limited, a microcap company specializing in bio coal briquettes and para-chloro-meta-cresol (PCMC), announced its Q4 FY25 results, showcasing an extraordinary turnaround. The company’s net sales skyrocketed by 12,000%+ year-on-year, leading to a significant boost in investor confidence and a 10% upper circuit hit on the BSE.
Hemo Organic Q4 results & FY25 Financial Highlights (Standalone)
- Net Sales: ₹2.41 crore, a massive increase from ₹0.02 crore in Q4 FY24 .
- Net Profit: ₹0.37 crore, up 261.93% from ₹0.23 crore in the same quarter last year.
- EBITDA: ₹0.24 crore, marking a 214.29% rise from ₹0.21 crore in Q4 FY24.
- Earnings Per Share (EPS): ₹1.08, compared to ₹0.67 in Q4 FY24.
Following the announcement, Hemo Organic’s stock surged to ₹10.65 on the BSE, hitting the 10% upper circuit limit . This reflects growing investor optimism about the company’s operational turnaround and future prospects.
Company Overview
Hemo Organic Limited, based in Gujarat, India, is engaged in the production and distribution of eco-friendly products like bio coal briquettes and PCMC, as well as Ayurvedic and Unani pharmaceutical preparations. The company has shown consistent growth, with an average three-year revenue growth of 48.57% and net profit growth of 61.78% .
Conclusion
Hemo Organic’s remarkable Q4 performance underscores its potential in the sustainable energy and pharmaceutical sectors. The significant increase in revenue and profitability indicates a successful strategic shift and operational efficiency. Investors and market watchers will be keenly observing the company’s trajectory in the coming quarters.
Disclaimer
The information provided in this article is for informational purposes only and does not constitute financial advice.Investors are advised to conduct their own research or consult a financial advisor before making investment decisions. Equitywatch is not responsible for any financial losses incurred.
